Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 12, 2016 - Issue 2
Submit an article Journal homepage
373
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Tools for studying drug transport and metabolism in the brain

Meagan R. PitcherTranslational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
&
João QuevedoTranslational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA;Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA;Neuroscience Graduate Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA;Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, Santa Catarina, BrazilCorrespondence[email protected]
Pages 161-168 | Received 03 Sep 2015, Accepted 11 Dec 2015, Published online: 08 Jan 2016

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6(7):521–532.
  • Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm. 2013;10(5):1492–1504.

• A review of fluid dynamics of the brain interstitial fluid.

  • Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 2014;11(1):26.

•• An excellent discussion of the current knowledge and caveats of the interactions between brain interstitial fluid and cerebrospinal fluid.

  • Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14.
  • Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20(10):1422–1449.

• An excellent review of drug delivery aspects to the brain.

  • Syvanen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radio ligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37(3):635–643.
  • O’Brien FE, O’Connor RM, Clarke G, et al. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology. 2013;38(11):2209–2219.
  • Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68(3):231–237.
  • Batrakova EV, Miller DW, Li S, et al. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther. 2001;296(2):551–557.
  • Agundez JA, Jimenez-Jimenez FJ, Alonso-Navarro H, et al. Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. Front Cell Neurosci. 2014;8:335.
  • Kondo A, Inoue T, Nagara H, et al. Neurotoxicity of adriamycin passed through the transiently disrupted blood-brain barrier by mannitol in the rat brain. Brain Res. 1987;412(1):73–83.
  • Neuwelt EA, Pagel M, Barnett P, et al. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res. 1981;41(11 Pt 1):4466–4470.
  • Aryal M, Vykhodtseva N, Zhang YZ, et al. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release. 2015;204:60–69.
  • Doolittle ND, Muldoon LL, Culp AY, et al. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol. 2014;71:203–243.
  • McDannold N, Arvanitis CD, Vykhodtseva N, et al. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012;72(14):3652–3663.
  • Alonso A. Ultrasound-induced blood-brain barrier opening for drug delivery. Front Neurol Neurosci. 2015;36:106–115.
  • Miller DS. Confocal imaging of xenobiotic transport across the choroid plexus. Adv Drug Deliv Rev. 2004;56(12):1811–1824.
  • Benarroch EE. Circumventricular organs: receptive and homeostatic functions and clinical implications. Neurology. 2011;77(12):1198–1204.

•• A thorough review and description of the circumventricular organs.

•• A description of the applications and design in BBB Trojan horse technology.

  • Zhao Y, Qu B, Wu X, et al. Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with “lock-in” function. Eur J Med Chem. 2014;82:314–323.
  • Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res. 2010;27(9):1759–1771.
  • Di L, Umland JP, Chang G, et al. Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos. 2011;39(7):1270–1277.
  • Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Reviews Neurol. 2015;11(8):457–470.
  • Spector R, Robert Snodgrass S, Johanson CE. A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans. Exp Neurol. 2015;273:57–68.
  • Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337–341.

• A description of the recently discovered CNS lymphatic vasculature.

  • Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov Today. 2009;14(21–22):1030–1036.
  • Passeleu-Le Bourdonnec C, Carrupt PA, Scherrmann JM, et al. Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research. Pharm Res. 2013;30(11):2729–2756.
  • Garberg P, Ball M, Borg N, et al. In vitro models for the blood-brain barrier. Toxicol In Vitro. 2005;19(3):299–334.
  • Thomsen LB, Burkhart A, Moos T. A triple culture model of the blood-brain barrier using porcine brain endothelial cells, astrocytes and pericytes. Plos One. 2015;10(8):e0134765.
  • Burkhart A, Thomsen LB, Thomsen MS, et al. Transfection of brain capillary endothelial cells in primary culture with defined blood-brain barrier properties. Fluids Barriers CNS. 2015;12(1):19.
  • Parikh NU, Aalinkeel R, Reynolds JL, et al. Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: neuroprotective role in maintaining blood brain barrier integrity. Brain Res. 2015;1624:175–187. DOI:10.1016/j.brainres.2015.07.033.
  • Hu HH, Bian YC, Liu Y, et al. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models. Int J Pharm. 2014;460(1–2):101–107.
  • Wang Q, Rager JD, Weinstein K, et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2005;288(2):349–359.
  • Pastan I, Gottesman MM, Ueda K, et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A. 1988;85(12):4486–4490.
  • Shi LZ, Li GJ, Wang S, et al. Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: tight junction proteins and transport properties. Toxicol In Vitro. 2008;22(1):190–199.
  • Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev. 2000;45(2–3):283–294.
  • de Lange EC, Danhof M, de Boer AG, et al. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev. 1997;25(1):27–49.
  • Singh AB, Bousman CA, Ng CH, et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. 2012;2:e198.
  • Lin KM, Chiu YF, Tsai IJ, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics. 2011;21(4):163–170.
  • Yang FY, Lin YL, Chou FI, et al. Pharmacokinetics of BPA in gliomas with ultrasound induced blood-brain barrier disruption as measured by microdialysis. Plos One. 2014;9(6):e100104.
  • Gunn RN, Murthy V, Catafau AM, et al. Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1. Synapse. 2011;65(12):1319–1332.
  • Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014;34(6):728–735.
  • Strohbehn G, Coman D, Han L, et al. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. J Neurooncol. 2015;121(3):441–449.
  • Puttick S, Bell C, Dowson N, et al. PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today. 2015;20(3):306–317.
  • Spector R, Keep RF, Robert Snodgrass S, et al. A balanced view of choroid plexus structure and function: focus on adult humans. Exp Neurol. 2015;267:78–86.
  • Lee H, Xie L, Yu M, et al. The effect of body posture on brain glymphatic transport. J Neuroscience. 2015;35(31):11034–11044.
  • Ali Khan A, Mudassir J, Mohtar N, et al. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733–2744.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.